Interestingly, we found that lung cancer cohorts with genetic alterations of EGFR, MAP2K1, mTOR, TEAD1, and YAP1 exhibited worse prognoses of overall, disease-specific, and progression-free survival compared to patients with wild-type (WT) genes (Figure 2D). This evidence concerns the gene YAP1 and lung carcinoma.